OBJECTIVES: To describe the current status of Pharmacoeconomic (PE) research in China from Jan 2002 through June 2013. METHODS: We conducted a review of pharmacoeconomic studies performed in China during Jan 2002 to June 2013. Using the Wanfang Chinese Database, we identified a total of 1338 articles. Keywords used are ‘Pharmacoeconomics’ or ‘Cost-Effectiveness Analysis’ or ‘Cost-Benefit Analysis’ or ‘Cost-Utility Analysis’ or ‘Cost’ or ‘Cost Study’ or ‘Economics Analysis’ all following by ‘(Healthcare and Medical Care)’ to exclude animal and other studies. Through a manual review, we excluded another 52 articles that did not align with study objectives. Article types selected are Journals, Academic Essays and Conference Essays. Descriptive analyses were performed to identify current trends, including number of articles by year, type of studies, and type of studies by year. RESULTS: A total of 1286 articles were conducted in China from 2002 to 2013. In general, the number of articles per year has been on the rise since 2002and appears to approach a steady state after 2007. Numbers of articles by year are 91 in 2002, 84 in 2003, 107 in 2004, 110 in 2005, 136 in 2006, 132 in 2007, 121 in 2008, 120 in 2009, 130 in 2010, 116 in 2011, 112 in 2012 and 27 during first half of 2013. The most common type of studies found were economic analyses (n=908/1286), of which cost-benefit analyses (n=395) were most commonly conducted. Two other common research types included treatment use (n=48) and application of PE (n=146), namely the role of PE to help determine price and inform healthcare management decisions. CONCLUSIONS: The development of Pharmacoeconomic research in China has been on a steady rise since 2002 with most output focused on economic modeling, followed by application of PE and treatment use.